vs
Amneal Pharmaceuticals, Inc.（AMRX）与亚玛芬体育（AS）财务数据对比。点击上方公司名可切换其他公司
亚玛芬体育的季度营收约是Amneal Pharmaceuticals, Inc.的1.5倍（$1.1B vs $722.5M），Amneal Pharmaceuticals, Inc.净利率更高（10.8% vs 1.8%，领先9.0%）
Amneal Pharmaceuticals是一家美国上市制药企业，核心业务涵盖仿制药及专科药物的研发、生产与分销，总部位于新泽西州布里奇沃特，是美国规模最大的仿制药生产商之一。
亚玛芬体育是芬兰跨国运动装备企业，总部位于赫尔辛基，成立于1950年。早年为涉足烟草贸易、航运、出版等领域的多元化工业集团，后逐步转型专注于体育用品的生产与营销，现有员工超9700人，2018年起成为中国安踏体育旗下子公司。
AMRX vs AS — 直观对比
营收规模更大
AS
是对方的1.5倍
$722.5M
净利率更高
AMRX
高出9.0%
1.8%
损益表 — Q1 FY2026 vs Q1 FY2024
| 指标 | | |
|---|---|---|
| 营收 | $722.5M | $1.1B |
| 净利润 | $78.0M | $19.0M |
| 毛利率 | 44.3% | 52.8% |
| 营业利润率 | — | 12.4% |
| 净利率 | 10.8% | 1.8% |
| 营收同比 | 3.9% | — |
| 净利润同比 | 217.0% | — |
| 每股收益（稀释后） | $0.19 | $0.05 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收AMRXAS
| Q1 26 | $722.5M | — | ||
| Q4 25 | $814.3M | — | ||
| Q3 25 | $784.5M | — | ||
| Q2 25 | $724.5M | — | ||
| Q1 25 | $695.4M | — | ||
| Q4 24 | $730.5M | — | ||
| Q3 24 | $702.5M | — | ||
| Q2 24 | $701.8M | — |
净利润AMRXAS
| Q1 26 | $78.0M | — | ||
| Q4 25 | $35.1M | — | ||
| Q3 25 | $2.4M | — | ||
| Q2 25 | $22.4M | — | ||
| Q1 25 | $12.2M | — | ||
| Q4 24 | $-31.1M | — | ||
| Q3 24 | $-156.0K | — | ||
| Q2 24 | $6.0M | — |
毛利率AMRXAS
| Q1 26 | 44.3% | — | ||
| Q4 25 | 36.5% | — | ||
| Q3 25 | 34.9% | — | ||
| Q2 25 | 39.5% | — | ||
| Q1 25 | 36.8% | — | ||
| Q4 24 | 36.0% | — | ||
| Q3 24 | 38.4% | — | ||
| Q2 24 | 35.6% | — |
营业利润率AMRXAS
| Q1 26 | — | — | ||
| Q4 25 | 13.8% | — | ||
| Q3 25 | 9.0% | — | ||
| Q2 25 | 15.4% | — | ||
| Q1 25 | 14.4% | — | ||
| Q4 24 | 10.4% | — | ||
| Q3 24 | 12.6% | — | ||
| Q2 24 | 13.6% | — |
净利率AMRXAS
| Q1 26 | 10.8% | — | ||
| Q4 25 | 4.3% | — | ||
| Q3 25 | 0.3% | — | ||
| Q2 25 | 3.1% | — | ||
| Q1 25 | 1.8% | — | ||
| Q4 24 | -4.3% | — | ||
| Q3 24 | -0.0% | — | ||
| Q2 24 | 0.9% | — |
每股收益（稀释后）AMRXAS
| Q1 26 | $0.19 | — | ||
| Q4 25 | $0.10 | — | ||
| Q3 25 | $0.01 | — | ||
| Q2 25 | $0.07 | — | ||
| Q1 25 | $0.04 | — | ||
| Q4 24 | $-0.10 | — | ||
| Q3 24 | $0.00 | — | ||
| Q2 24 | $0.02 | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $114.3M |
| 自由现金流经营现金流 - 资本支出 | — | $92.2M |
| 自由现金流率自由现金流/营收 | — | 8.8% |
| 资本支出强度资本支出/营收 | — | 2.1% |
| 现金转化率经营现金流/净利润 | — | 6.02× |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
经营现金流AMRXAS
| Q1 26 | — | — | ||
| Q4 25 | $130.3M | — | ||
| Q3 25 | $118.5M | — | ||
| Q2 25 | $83.8M | — | ||
| Q1 25 | $7.4M | — | ||
| Q4 24 | $118.1M | — | ||
| Q3 24 | $141.8M | — | ||
| Q2 24 | $39.7M | — |
自由现金流AMRXAS
| Q1 26 | — | — | ||
| Q4 25 | $108.5M | — | ||
| Q3 25 | $106.2M | — | ||
| Q2 25 | $61.0M | — | ||
| Q1 25 | $-5.8M | — | ||
| Q4 24 | $102.9M | — | ||
| Q3 24 | $124.8M | — | ||
| Q2 24 | $29.0M | — |
自由现金流率AMRXAS
| Q1 26 | — | — | ||
| Q4 25 | 13.3% | — | ||
| Q3 25 | 13.5% | — | ||
| Q2 25 | 8.4% | — | ||
| Q1 25 | -0.8% | — | ||
| Q4 24 | 14.1% | — | ||
| Q3 24 | 17.8% | — | ||
| Q2 24 | 4.1% | — |
资本支出强度AMRXAS
| Q1 26 | — | — | ||
| Q4 25 | 2.7% | — | ||
| Q3 25 | 1.6% | — | ||
| Q2 25 | 3.2% | — | ||
| Q1 25 | 1.9% | — | ||
| Q4 24 | 2.1% | — | ||
| Q3 24 | 2.4% | — | ||
| Q2 24 | 1.5% | — |
现金转化率AMRXAS
| Q1 26 | — | — | ||
| Q4 25 | 3.72× | — | ||
| Q3 25 | 50.00× | — | ||
| Q2 25 | 3.74× | — | ||
| Q1 25 | 0.61× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | 6.62× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
AMRX
| Affordable Medicines net | $423.0M | 59% |
| AvKARE net | $166.0M | 23% |
| Specialty net | $133.0M | 18% |
AS
| Americas2 | $409.6M | 39% |
| EMEA1 | $356.9M | 34% |
| Greater China3 | $205.6M | 20% |
| Asia Pacific4 | $78.2M | 7% |
